Next to counteracting the don’t-eat-me signal, nanobodies targeting SIRPα could also be used to deplete tumor-promoting myeloid cells, which facilitate GBM development and protect it from therapeutic treatments (61). The gene discussed is SIRPA; the disease is glioblastoma.